Henan Cancer Hospital

Henan Cancer Hospital logo
🇨🇳China
Ownership
Private
Established
1977-01-01
Employees
-
Market Cap
-
Website
http://www.anti-cancer.com.cn

A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

First Posted Date
2021-03-03
Last Posted Date
2021-08-31
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
60
Registration Number
NCT04778800
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma

First Posted Date
2021-02-04
Last Posted Date
2023-05-18
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
30
Registration Number
NCT04737889
Locations
🇨🇳

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

First Posted Date
2020-12-23
Last Posted Date
2023-09-25
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
46
Registration Number
NCT04681287
Locations
🇨🇳

Henan cancer hospital, Zhengzhou, Henan, China

Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer

First Posted Date
2020-12-19
Last Posted Date
2022-04-15
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
46
Registration Number
NCT04675866
Locations
🇨🇳

Henan Tumor Hospital, Ho-nan, Henan, China

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

First Posted Date
2020-12-16
Last Posted Date
2023-05-18
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
59
Registration Number
NCT04668365
Locations
🇨🇳

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China

Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC

First Posted Date
2020-12-11
Last Posted Date
2024-04-15
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
212
Registration Number
NCT04664972
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

First Posted Date
2020-12-09
Last Posted Date
2022-04-12
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
120
Registration Number
NCT04660097
Locations
🇨🇳

Henan Tumor Hospital, Zhengzhou, Henan, China

A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System Tumors

First Posted Date
2020-11-04
Last Posted Date
2021-08-23
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
50
Registration Number
NCT04615312
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

First Posted Date
2020-09-18
Last Posted Date
2021-11-26
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
50
Registration Number
NCT04553939
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

© Copyright 2024. All Rights Reserved by MedPath